ArticleIndian journal of ophthalmology2026
Clinical assessment of visual outcomes and safety in Indian cataract patients implanted with the Optiflex Trio trifocal intraocular lens.
Article in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study evaluates the performance and safety of the Optiflex Trio trifocal intraocular lens (IOLs) in Indian cataract patients.
designSingle-arm prospective clinical study.
methodsPatients undergoing phacoemulsification for senile cataracts received bilateral Optiflex Trio trifocal IOLs. Visual outcomes, spherical equivalent, reading performance, contrast sensitivity, stereo acuity, and high-order aberrations were assessed at 1 week, 1 month, 3 months, 6 months, and 12 months.
resultsA total of 93 eyes were implanted with IOL and showed significant improvement from pre-op to 12 months in the uncorrected distance (UDVA: 0.74 ± 0.33 to 0.01 ± 0.04 logMAR, P = 0.0001), intermediate (UIVA: 0.62 ± 0.20 to 0.01 ± 0.03 logMAR, P = 0.0001) and near visual acuity (UNVA: 0.57 ± 0.20 to 0.01 ± 0.02 logMAR, P = 0.0001), best-corrected distance visual acuity (BCDVA: 0.45 ± 0.29 to 0.00 ± 0.01 logMAR, P = 0.0001), and distance-corrected visual acuities (DCIVA and DCNVA: 0.32 ± 0.23 to 0.00 logMAR, P = 0.0001). The contrast sensitivity increased from 0.52 ± 0.40 to 1.49 ± 0.05 ( P = 0.0001), while high-order and total aberrations decreased (0.87 ± 0.71 to 0.16 ± 0.11 µm and 1.55 ± 1.13 to 0.21 ± 0.07 µm, both P = 0.0001). Near/intermediate reading speeds improved by 5.18 ± 8.72 and 5.15 ± 8.72 words/min ( P = 0.000). Stereo acuity significantly enhanced, with FD2 from 265.14 ± 124.93 to 83.41 ± 12.56 and Near Radnor from 211.71 ± 114.60 to 74.77 ± 6.98 ( P < 0.0001). No adverse events were reported.
conclusionOptiflex Trio trifocal IOL enhances vision, reduces aberrations, and supports spectacle independence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.